These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34703332)

  • 21. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.
    Chopra I; Qin Y; Kranyak J; Gallagher JR; Heap K; Carroll S; Wan GJ
    Ther Adv Respir Dis; 2019; 13():1753466619888127. PubMed ID: 31722624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series.
    Brown AN
    Open Access Rheumatol; 2016; 8():97-102. PubMed ID: 27956846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model.
    Hayes K; Warner E; Bollinger C; Wright D; Fitch RM
    BMC Nephrol; 2020 Jun; 21(1):226. PubMed ID: 32539845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies.
    Fischer PA; Rapoport RJ
    Open Access Rheumatol; 2018; 10():13-19. PubMed ID: 29445306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
    Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
    Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
    Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world effects of Yishen Tongbi decoction for rheumatoid arthritis: protocol for a prospective, observational, multicenter cohort study with validation against double-blind, randomized, controlled trial.
    Liu L; Zhu F; Xin Y; Zhang L; Hu C; Xu Y; Zhang J; Liu L; Chen G
    Front Pharmacol; 2024; 15():1320578. PubMed ID: 38410132
    [No Abstract]   [Full Text] [Related]  

  • 29. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
    Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
    Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology.
    Yun H; Chen L; Xie F; Patel H; Boytsov N; Zhang X; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):166-175. PubMed ID: 31566905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
    Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH
    Poola N; Due B; Wright D; Brooks LR; Zaman F
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):502-515. PubMed ID: 34528408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Repository Corticotropin Injection on Medication Use in Patients With Rheumatologic Conditions: A Claims Data Study.
    Myung G; Nelson WW; McMahon MA
    J Pharm Technol; 2017 Aug; 33(4):151-155. PubMed ID: 34861677
    [No Abstract]   [Full Text] [Related]  

  • 34. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms.
    Gold LS; Nazareth TA; Yu TC; Fry KR; Mahler NH; Rava A; Waltrip Ii RW; Hansen RN
    Pediatric Health Med Ther; 2019; 10():195-207. PubMed ID: 32099512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
    Kaplan J; Miller T; Baker M; Due B; Zhao E
    Front Neurol; 2020; 11():598496. PubMed ID: 33414758
    [No Abstract]   [Full Text] [Related]  

  • 36. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
    Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
    CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acthar
    Kaplan J; Askanase A; Chu D; Abdellatif A; Basu D; Mirsaeidi M
    Clin Drug Investig; 2023 Oct; 43(10):739-761. PubMed ID: 37792273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis.
    Fleischmann R; Liu J; Zhu J; Segurado OG; Furst DE
    Arthritis Care Res (Hoboken); 2022 Sep; 74(9):1477-1483. PubMed ID: 33644992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.